FDA approves Axsome's novel migraine treatment SYMBRAVO
This news article is based on a press release statement from Axsome Therapeutics (NASDAQ:AXSM). The company continues to focus on addressing critical gaps in CNS treatment and advancing patient ...
FiercePharma1h
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Meloxicam is a non-steroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Axsome gets FDA approval for Symbravo for migraine
Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or ...